Article Details
Retrieved on: 2021-10-26 15:35:20
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Monoclonal antibodies infliximab and adalimumab (pictured) are licensed for both ulcerative colitis and Crohn's disease with comparable efficacy.
Article found on: pharmaceutical-journal.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here